Our Publications
From the lab
ILC2s in cancer: good, bad, or stay tuned?
Trends in Molecular Medicine, 2025
Asif S.*, Kinzel M.*, Vanderhyden B.†, Jacquelot N.†, Ardolino M.†
*co-first author
† co-senior author
LAG3 marks activated but hyporesponsive NK cells
European Journal of Immunology, 2025, 55(7), e70009
Vasilyeva V., Makinson O., Chan C., Park M., O’Dwyer C., Ali A., Khan A.U.H., Tanese de Souza C., Hasim M.S., Asif S., Kurdieh R., Abou-Hamad J., Yakubovich E., Hodgins J., Al Haddad P., Pietropaolo G., Mazej J., Seo H., Huang Q., Nersesian S., Chay D., Jacquelot N., Cook D., Lee S.H., Sciume G., Waggoner S., Ardolino M.*, Marotel M.*
*co-senior author
PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
Journal of Experimental Medicine, 2024, 221(7), e20221721
Hodgins J.J., Abou-Hamad J., O’Dwyer C.E., Hagerman A., Yakubovich E., Tanese de Souza C., Marotel M., Buchler A., Fadel S., Park M.M., Fong-McMaster C., Crupi M.F., Makinson O.J., Kurdieh R., Rezaei R., Dhillon H.S., Ilkow C.S., Bell J.C., Harper M-E., Rotstein B.H., Auer R.C., Vanderhyden B.C., Sabourin L.A., Bourgeois-Daigneault M-C., Cook D.P., Ardolino M.
CD8 T cell hyperfunction and reduced tumour control in models of advanced liver fibrosis
Submitted to BioRxiv
Madani J., Li J., Vranjkovic A., Jorritsma K., Hasim M.S., Daneshmand M., Cheung A.C., Ching A.M.E., Bruin J.E., Ardolino M.*, Crawley A.M.*
*co-senior author
P-022 Development of trogocytosis resistant CAR-NK for multiple myeloma
Clin. Lymphoma Myeloma Leuk., 2023, 23, S45.
Kilgour M.K., Kaczmarek S., Lee S.H., McComb S., Visram A., Ardolino M.
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
Front. In Immunol., 2023, 14
Kilgour M.K., Bastin D.J., Lee S.H.*, Ardolino M.*, McComb S.*, Visram A.*
*co-senior author
More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway
Submitted to BioRxiv
Hodgins J.J., Abou-Hamad J., Hagerman A., Yakubovich E., Tanese de Souza C., Marotel M., Buchler A., Fadel S., Park M., Fong-McMaster C., Crupi M., Bell J.C., Harper M-E., Rotstein B.H., Auer R.C., Vanderhyden B., Sabourin L., Bourgeois-Daigneault M.C., Cook D., Ardolino M.
A new functional screening platform identifies colistin sulfate as an enhancer of Natural Killer cell cytotoxicity.
Cancers, 2022, 14(12), 2832
Cortés-Kaplan S., Hasim M.S., Kaczmarek S., Taha Z., Maznyi G., McComb S., Lee S.H., Diallo J.S., Ardolino M.
When Killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer
Science Advances, 2022, 8(15)
Hasim M.S.†, Marotel M.†, Hodgins J.J., Vulpis E., Makinson O.J., Asif S., Shih H.Y., Scheer A.K., MacMillan O., Alonso F.G., Burke K.P., Cook D.P., Li R., Petrucci M.T., Santoni A., Fallon P.G., Sharpe A.H., Sciumè G., Veillette A., Zingoni A., Gray D.A., McCurdy A., Ardolino M.
†: equal contribution
Immunotherapy for sarcomas: new frontiers and unveiled opportunities.
Journal of Immunotherapy of Cancer, 2021, 9(2):e001580
K. Birdi#, A. Jirovec#, S. Cortés-Kaplan#, J. Werier, C. Nessim, J.S. Diallo*, M. Ardolino*
#: equal contribution / *: equal contribution
The two faces of NK cells in oncolytic virotherapy
Cytokines and Growth Factors Reviews, 2020, 11:1512
Marotel M., Hasim M.S., Hagerman A., Ardolino M.
Flattening the COVID-19 curve with Natural Killer cell based immunotherapies
Frontiers in Immunology, 2020, 11:1512
Market M., Angka L., Martel A., Bastin D., Olanubi O., Tennakoon G., Boucher D., Ng J., Ardolino M.*, Auer R.C.*
*corresponding author and co-senior author
Is Innate Immunity our best weapon for flattening the curve?
The Journal of Clinical Investigation, 2020, 130(8):3954-3956
Angka L., Market M., Ardolino M.*, Auer R.C.*
*corresponding author and co-senior author
Killers 2.0: NK Cell Therapies at the Forefront of Cancer Control.
The Journal of Clinical Investigation, 2019, 129(9):3499-3510
Hodgins J.J., Khan S.T., Park M., Auer R.C., Ardolino M.
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
The Journal of Clinical Investigation, 2018, 128(10):4654-4688
Hsu J.+, Hodgins J.J.+, Marathe M., Nicolai C.J., Bourgeois-Daigneault M.C., Trevino T.N., Azimi C.S., Scheer A.K., Randolph H.E., Thompson T.W., Zhang L., Iannello A., Mathur N., Jardine K.E., Kirn G.A., Bell J.C., McBurney M.W., Raulet D.H.*, Ardolino M.*
*co-corresponding authors and co-senior authors
Collaborations
CD8 T cell hyperfunction and reduced tumour control in murine models of advanced liver disease
European Journal of Immunology, 2025, 55(8), e70026
Madani J., Li J., Ching M.E.A., Vranjkovic A., Jorritsma K., Hasim M.S., Daneshmand M., Campeau N., Lawton D.A., Bagheri S., Cheung A.C., Mulvihill E.E., Bruin J.E., Ardolino M., Crawley A.M.
Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies
Cytotherapy, 2025, 27(3), 350–364
Bastin D.J., Kilgour M.K., Shorr R., Sabri E., Delluc A., Ardolino M., McComb S., Lee S.H., Allan D., Ramsay T., Visram A.
Metabolic dysfunction drives CD8 T cell hyperfunction and impaired tumor responses in mouse models of advanced liver disease
Hepatology, 2024, 80, S744–S745. Lippincott Williams & Wilkins
Li J., Jorritsma K., Campeau N., Vranjkovic A., Madani J., Alothaimeen T., Cheung A., Ardolino M., Crawley A.
Preventing surgery-induced immune suppression and metastases by inhibiting PI3K-gamma signalling in myeloid-derived suppressor cells
Submitted to BioRxiv
Angka L., Tennakoon G., Cook D.P., Martel A.B., Market M., Tanese de Souza C., Cummins E., Samudio I., Kekre N., Ardolino M., Vanderhyden B., Kennedy M.A., Auer R.C.
Evaluation of resazurin phenoxazine dye as a highly sensitive cell viability potency assay for natural killer cell-derived extracellular vesicle-based cancer biotherapeutics
Journal of Extracellular Biology, 2024, 3(7), e166
St-Denis-Bissonnette F., Qiu S., Cummings S.E., Kirkby M., Haile Y., Wassmer S., Muradia G., Mehic J., Stalker A., Shrestha A., Ardolino M., Lee S.H., Burger D., Wang L., Lavoie J.R.
Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model
Frontiers in Immunology, 2024, 15, Article 1366197
Mediratta K., El-Sahli S., Marolet M., Awan M.Z., Kirkby M., Salkini A., Reukrich R., Abdisalam S., Shrestha A., Di Censo C., Sulaiman A., McGarry S., Lavoie J.R., Liu Z., Lee S.H., D’Costa V.M., Ardolino M., Wang L.
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors
Nature Cancer, 2024, 5, 463–480
Bergin C.J., Zouggar A., Mendes da Silva A., Fenouil T., Haebe J.R., Masibag A.N., Agrawal G., Shah M.S., Sandouka T., Tiberi M., Auer R.C., Ardolino M., Benoit Y.D.
FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models
Scientific Reports, 2024, 14, Article 787
Galpin K.J.C., Rodriguez G.M., Maranda V., Cook D.P., Macdonald E., Murshed H., Zhao S., McCloskey C.W., Chruscinski A., Levy G.A., Ardolino M., Vanderhyden B.C.
Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses
Cells, 2024, 13(1), 73.
Abou-Hamad J., Hodgins J.J., Yakubovich E., Vanderhyden B.C., Ardolino M., Sabourin L.
Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies.
Nature Communications, 2023, 14
Azad T., Rezaei R., Singaravelu R., Pelin A., Boulton S., Petryk J., Onsu K.A., Martin N.T., Hoskin V., Ghahremani M., Marotel M., Marius R., He X., Crupi M.J.F., Hoang H-D., Nik-Akhtar A., Ahmadi M., Zamani N.K., Golshani A., Alain T., Greer P., Ardolino M., Dickinson B.C., Tai L-H., Ilkow C.S., Bell J.C.
CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness
iScience, 2022, 25(12):105524
Abou-Hamad J, Hodgins JJ, de Souza CT, Garland B, Labrèche C, Marotel M, Gibson C, Delisle S, Pascoal J, Auer RC, Ardolino M, Sabourin L
Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver
European Journal of Immunology, 2021, 51(11):2568-2575
Di Censo C., Marotel , Mattiola I., Müller L., Scarno G., Pietropaolo G., Peruzzi G., Laffranchi M., Mazej J., Hasim M.S., Asif S., Russo E., Tomaipitinca L., Stabile H., Lee S.H., Vian L., Gadina M., Gismondi A., Shih H.-Y., Mikami Y., Bernardini G., Bonelli M., Sozzani S., Diefenbach A., Ardolino M., Santoni A., Sciumè G.
Muscle-Specific Deletion of SLK/Stk2 Enhances p38 Activity and Myogenesis in mdx Mice
BBA Molecular Cell Research, 2021, 1868(2), 118917
Pryce B.P., Labreche C., Hamoudi D., Abou-Hamad J., Al-Zahrani K.N., Hodgins J.J., Boulanger-Piette A., Bossé S., Balog-Alvarez C., Frenette J., Ardolino M., Kornegay J.N., Sabourin L.
Loss of Ste20-like kinase induces a basal/stem-like phenotype in HER2-positive breast cancers.
Oncogene, 2020, 39(23):4592-4602
Al-Zahrani K., Abou-Hamad J., Pryce B., Cook D., Hodgins J.J., Labreche C., Robineau‑Charette P., de Souza C., Bell J.C., Auer R.C., Ardolino M., Vanderhyden B., Sabourin L.
Contact Us
Address: Ottawa Hospital Research Institute – 501 Smyth Road – Cancer Center – Ottawa, ON K1H 8M2
Tel: 613-737-8899 ext 77253
Mail: mardolino@ohri.ca
Legal Informations
Made with love by Qweeble